Management of Side-Effects of Antiepileptic Drugs

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 289-299

  Zaccara, Gaetano ^a   Balestrieri, Fabrizio ^a   Ragazzoni, Aldo ^a  

^a Palagi Hospital   (Italy)

Author keywords

Antiepileptic drug management of side effects; Antiepileptic drugs and adverse effects; Baseline screening laboratory examinations; Daily regimens and chrono formulations; Encephalopathies and AEDs intoxication; Risk factor analysis; Strategies for prevention or minimization of adverse effects

Indexed keywords

EID: 84865135585     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch22     Document Type: Chapter

References (52)

1. Loiseau P. Tolerability of newer and older anticonvulsants: a comparative review. CNS Drugs 1996; 6: 148-166.
2. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223-1244.
3. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand 2005; 181(Suppl): S30-S35.
4. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008; 17: 405-421.
5. Camfield P, Camfield C. Monitoring for adverse effects of antiepileptic drugs. Epilepsia 2006; 47(Suppl. 1): 31-34.
6. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-151.
7. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-771.
8. Genton P, Gelisse P. Valproic acid. Adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002: 837-851.
9. Leppik IE. Felbamate. In: Shorvon S, Perucca E, Fish D, Dodson E (eds). The Treatment of Epilepsy, 2nd edn. Oxford: Blackwell Publishing, 2004: 403-409.
10. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl J Med 1990; 322: 364-369.
11. Aldenkamp AP, De Krom MDe, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 4: 21-29.
12. Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. Motor adverse effects induced by antiepileptic drugs. Epileptic Disorders 2004; 6: 153-168.
13. Dam M. The Density and Ultrastructure of the Purkinje Cells Following Diphenylhydantoin Treatment in Animals and Man. Copenhagen: Bogtrykkeriet Forum, 1972.
14. Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Valproate tremors. Neurology 1982; 32: 428-432.
15. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-880.
16. Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993; 8: 19-27.
17. Zaccara G, Campostrini R, Paganini M, et al. Acute changes of blood ammonia concentrations may help to predict valproic acid short-term adverse effects. Neurology 1984; 34: 1519-1521.
18. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42: 790-792.
19. Sharif MK, Sander JWA, Shorvon SD. Acute encephalopathy with vigabatrin. Lancet 1993; 342: 619.
20. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181-184.
21. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007; 30: 555-567.
22. http://www.fda.gov/cder/drug/InfoSheets/HCP/antiepilepticsHCP.htm.
23. Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric co morbidity. Neurology 2006; 67(Suppl. 4): S39-S44.
24. Brandt C, Fueratsch N, Boehme V, et al. Development of psychosis in patients with epilepsy treated with lamotrigine. Report of six cases and review of the literature. Epilepsy Behav 2007; 11: 133-139.
25. Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659-663.
26. Gissell T, Sondergaard C, Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf 2007; 6: 267-278.
27. Bruni J. Adverse effects of phenytoin. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelpia: Lippincott Williams & Wilkins, 2002: 605-610.
28. Sachdeo RC, Karia RM. Adverse effects of topiramate. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelpia: Lippincott Williams & Wilkins, 2002: 760-764.
29. Biton V. Weight change and antiepileptic drugs. Health issues and criteria for appropriate selection of an antiepileptic agent. Neurologist 2006; 12: 163-167.
30. Holmes GL. Adverse effects of carbamazepine. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002: 285-294.
31. Kalviainen R and Nousiainen I. Visual defects with vigabatrin. Epidemiology and therapeutic implications. CNS Drugs 2001; 15: 217-230.
32. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate, associated, acute, secondary angle-closure glaucoma. Ophthalmology 2004; 111: 109-111.
33. Chadwick D, Shaw MDM, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentration and the drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642-644.
34. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998; 18: 281-296.
35. Peyrière H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Therapeutics 2006; 155: 422-428.
36. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-546.
37. Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265-1269.
38. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nature Reviews 2005; 4: 489-499.
39. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989; 139: 201-207.
40. Kapetanovic IM, Torchin CD, Strong JM, et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 2002; 142: 119-134.
41. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drugs use in the elderly. Epilepsy Res 2006; 68(Suppl. 1): 49-63.
42. Johnson TN. The development of drug metabolizing enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 37-48.
43. Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia 2000; 41: 488.
44. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research 1999; 37: 81-87.
45. Perucca E, Kwan P. Overtreatment in epilepsy. Drugs 2005; 19: 897-908.
46. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998; 39: 1216-1225.
47. Lee AY, Kim MJ, Chey WY, et al. Genetic polymorphism of cytochrome P4502C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004; 60: 155-159.
48. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
49. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268.
50. http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm.
51. Canger R, Altamura AC, Belvedere O, et al. Conventional vs controlledrelease carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand 1990; 82: 9-13.
52. Gilliam FG, Fessler AJ, Baker G, et al. Systematic screening allows reduction of adverse antiepileptic drug effects. A randomised trial. Neurology 2004; 62: 23-27.